Literature DB >> 24300485

[Role of proinflammatory cytokines in the development and progression of micro- and macroangiopathies in patients with type 2 diabetes mellitus].

A A Nelaeva, Iu V Khasanova, E S Khobotova.   

Abstract

Diabetes mellitus is a systemic lesion of the micro- and macrocirculatory bed. We examined a total of 110 people with type 2 diabetes mellitus and lesions of the major vessels of the lower limbs. Of these, 70 patients were found to have microangiopathy combined with nephropathy. Diabetic nephropathy was classified depending on the level of microalbuminuria and the glomerular filtration rate. All patients were subdivided into three groups: diabetic macroangiopathy of the lower extremities with neither diabetic nephropathy nor chronic renal disease, lower-limb diabetic macroangiopathy combined with diabetic nephropathy in stage 1 of microalbuminuria of chronic renal disease and those in combination with diabetic nephropathy in stage 2 of microalbuminuria chronic renal disease. We measured the level of interleukine-6 and interleukine-8, tumour necrosis factor α, fibrinogen and the von Willebrand factor, revealing simultaneous progression of lower limb angiopathy in diabetic nephropathy, with direct interrelation between proinflammatory cytokines and the haemostasis system parameters. A decrease in the interleukine-8 level as nephropathy progresses may be indicative of exhaustion of angiogenesis, which is one of the factors of progression of macroangiopathy in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24300485

Source DB:  PubMed          Journal:  Angiol Sosud Khir        ISSN: 1027-6661


  1 in total

1.  Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.

Authors:  Hong Gao; Yuhong Duan; Xiaoxu Fu; Hongyan Xie; Ya Liu; Haipo Yuan; Mingyang Zhou; Chunguang Xie
Journal:  PLoS One       Date:  2018-12-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.